332 related articles for article (PubMed ID: 19104471)
1. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Chantratita W; Nakamura Y
Pharmacogenet Genomics; 2009 Feb; 19(2):139-46. PubMed ID: 19104471
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.
Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Takahashi A; Kubo M; Kamatani N; Chantratita W; Nakamura Y
Clin Infect Dis; 2011 Aug; 53(4):341-8. PubMed ID: 21810746
[TBL] [Abstract][Full Text] [Related]
3. Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen.
Wangsomboonsiri W; Mahasirimongkol S; Chantarangsu S; Kiertiburanakul S; Charoenyingwattana A; Komindr S; Thongnak C; Mushiroda T; Nakamura Y; Chantratita W; Sungkanuparph S
Clin Infect Dis; 2010 Feb; 50(4):597-604. PubMed ID: 20073992
[TBL] [Abstract][Full Text] [Related]
4. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
[TBL] [Abstract][Full Text] [Related]
6. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
7. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.
Littera R; Carcassi C; Masala A; Piano P; Serra P; Ortu F; Corso N; Casula B; La Nasa G; Contu L; Manconi PE
AIDS; 2006 Aug; 20(12):1621-6. PubMed ID: 16868443
[TBL] [Abstract][Full Text] [Related]
8. Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.
Launay O; Roudière L; Boukli N; Dupont B; Prévoteau du Clary F; Patey O; David F; Lortholary O; Devidas A; Piketty C; Rey E; Urbinelli R; Allaert FA; Tréluyer JM; Caumes E;
Clin Infect Dis; 2004 Apr; 38(8):e66-72. PubMed ID: 15095233
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A
Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514
[TBL] [Abstract][Full Text] [Related]
10. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
Kiertiburanakul S; Malathum K; Watcharananan S; Sathapatayavongs B; Sungkanuparph S
Int J STD AIDS; 2009 Mar; 20(3):176-9. PubMed ID: 19255265
[TBL] [Abstract][Full Text] [Related]
11. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
João EC; Calvet GA; Menezes JA; D'Ippolito MM; Cruz ML; Salgado LA; Matos HJ
Am J Obstet Gynecol; 2006 Jan; 194(1):199-202. PubMed ID: 16389032
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
[TBL] [Abstract][Full Text] [Related]
13. Oral adverse effects due to the use of Nevirapine.
Moura MD; Senna MI; Madureira DF; Fonseca LM; Mesquita RA
J Contemp Dent Pract; 2008 Jan; 9(1):84-90. PubMed ID: 18176653
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.
Shenton JM; Teranishi M; Abu-Asab MS; Yager JA; Uetrecht JP
Chem Res Toxicol; 2003 Sep; 16(9):1078-89. PubMed ID: 12971795
[TBL] [Abstract][Full Text] [Related]
15. Serious toxicity associated with continuous nevirapine-based HAART in pregnancy.
van Schalkwyk JE; Alimenti A; Khoo D; Maan E; Forbes JC; Burdge DR; Gilgoff S; Money DM
BJOG; 2008 Sep; 115(10):1297-302. PubMed ID: 18715416
[TBL] [Abstract][Full Text] [Related]
16. Development of new HLA-B*3505 genotyping method using Invader assay.
Hosono N; Chantarangsu S; Kiyotani K; Takata S; Tsuchiya Y; Mahasirimongkol S; Chantratita W; Mushiroda T; Nakamura Y; Kubo M
Pharmacogenet Genomics; 2010 Oct; 20(10):630-3. PubMed ID: 20679961
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine bioactivation and covalent binding in the skin.
Sharma AM; Klarskov K; Uetrecht J
Chem Res Toxicol; 2013 Mar; 26(3):410-21. PubMed ID: 23387501
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A
J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979
[TBL] [Abstract][Full Text] [Related]
19. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
Sankatsing RR; Wit FW; Pakker N; Vyankandondera J; Mmiro F; Okong P; Kastelein JJ; Lange JM; Stroes ES; Reiss P
J Infect Dis; 2007 Jul; 196(1):15-22. PubMed ID: 17538878
[TBL] [Abstract][Full Text] [Related]
20. Nevirapine-associated rash in a Jamaican child with HIV/AIDS.
Steel-Duncan JC; Pierre R; Gabay L; Christie CD
West Indian Med J; 2004 Oct; 53(5):356-8. PubMed ID: 15675504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
